Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
AI Predicts Outcomes After Hip Replacement Surgery Using Gait Data
Researchers developed an explainable AI model to predict recovery after hip replacement by analyzing patients' gait biomechanics.
•EurekAlert
AI Model Achieves Accurate Prenatal Detection of Placenta Accreta
An AI model accurately identified all cases of placenta accreta spectrum in a high-risk pregnancy cohort using ultrasound images.
•EurekAlert
Mount Sinai Researchers Unveil AI Models for Pregnancy Risk Prediction at SMFM 2026
Mount Sinai specialists debut AI and machine learning models targeting prediction and screening for severe pregnancy complications using imaging and EMR data at SMFM 2026.